Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer

作者
Tao Tang,Jingtai Zhi,Wei Zhang,Linfei Hu,Xianhui Ruan,Xiaoyu Chen,Zhaohui Wang,Xiangqian Zheng,Ming Gao
出处
期刊:Journal of Healthcare Engineering [Hindawi Publishing Corporation]
卷期号:2022: 1-9 被引量:3
标识
DOI:10.1155/2022/4348396
摘要

Purpose: The purpose of the current study was to determine whether older patients with differentiated thyroid cancer (DTC) who received surgical treatment had a better cause-specific survival (CSS) than patients who were recommended surgery, but declined, and whether patients who underwent postoperative RAI-131 therapy had an impact on CSS based on TNM staging and number of lymph node metastases for all total or near-total thyroidectomy patients. Patients and Methods: This retrospective, population-based study analyzed the clinical data of 162 DTC patients from signal institution in China and 26,487 cases from the Surveillance, Epidemiology, and End Results (SEER) program registry. The patients were divided into two groups (underwent surgery and surgery recommended, but not performed) in the SEER cohort. Furthermore, patients were grouped as follows: T4; N1b; M1; T1-3N0-1a; specific number of lymph node metastases; and total or near-total thyroidectomy. Results: The 120-month cause-specific survival (CSS) rate of women and men showed a gradual declining trend from 60–64 to ≥80 years of age in the group that underwent surgery. The CSS rate of women and men showed a marked downward and irregular trend with an increase in age in the recommended, but no surgery group in the SEER cohort. Univariate analysis indicated that the surgery group had a higher 120-month CSS in women in most stages and men, compared with the no surgery group in the SEER cohort. The analysis of the SEER cohort showed that RAI-131 therapy was associated with an improved 80-month CSS in T4/N1b/M1 women ( P < 0.0183 ) and men ( P < 0.0011 ). However, there were no CSS differences between the RAI-131 therapy and the no-RAI-131 group for the patients with T4/N1b/M1 (AJCC 7th) thyroid cancer in the Chinese cohort. There was no CSS difference in women or men between the T1-3N0 and T1-3N1a patients in the SEER cohort. And similar findings were observed in T1-3N1a patients in the Chinese cohort. There was no statistical difference between the two subgroups. Conclusions: Surgical treatment should be recommended for elderly DTC patients because surgery can lead to a better CSS. High-risk patients achieve a higher benefit-to-risk ratio with RAI-131 therapy. To avoid the adverse effects associated with RAI-131 therapy, a multidisciplinary discussion should be arranged for intermediate- and low-risk patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
2秒前
中华大团团应助YangZhang采纳,获得10
2秒前
3秒前
Love完成签到,获得积分20
4秒前
4秒前
呵呵完成签到,获得积分10
6秒前
uu发布了新的文献求助10
6秒前
tanlaker发布了新的文献求助10
7秒前
青青完成签到 ,获得积分10
7秒前
7秒前
猪猪hero发布了新的文献求助10
8秒前
8秒前
8秒前
科研通AI6.4应助totootwo采纳,获得10
9秒前
fabian完成签到,获得积分10
11秒前
13秒前
magie发布了新的文献求助10
13秒前
13秒前
14秒前
yao学渣完成签到 ,获得积分10
14秒前
NexusExplorer应助zzzzz采纳,获得10
14秒前
Butterfly完成签到,获得积分10
15秒前
15秒前
Eclipse12138完成签到,获得积分10
15秒前
狂野紫丝发布了新的文献求助10
18秒前
xiaobao完成签到,获得积分0
18秒前
orixero应助4477采纳,获得10
18秒前
18秒前
猪猪hero发布了新的文献求助10
18秒前
kitty发布了新的文献求助10
19秒前
19秒前
小二郎应助暂未成功人士采纳,获得10
19秒前
19秒前
FashionBoy应助扣扣采纳,获得10
20秒前
20秒前
21秒前
大模型应助山野的雾采纳,获得10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HYDROLYSE ACIDE DE QUELQUES DIOXASPIROCYCLANES 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 600
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7740792
求助须知:如何正确求助?哪些是违规求助? 9289359
关于积分的说明 20195369
捐赠科研通 7318948
什么是DOI,文献DOI怎么找? 3306533
关于科研通互助平台的介绍 2458816
邀请新用户注册赠送积分活动 2316786